Next Article in Journal
An Unusual Diterpene—Enhygromic Acid and Deoxyenhygrolides from a Marine Myxobacterium, Enhygromyxa sp.
Previous Article in Journal
Pharmacophore-Based Virtual Screening of Novel Inhibitors and Docking Analysis for CYP51A from Penicillium italicum
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Mar. Drugs 2017, 15(4), 106; doi:10.3390/md15040106

The Effect of Phloroglucinol, A Component of Ecklonia cava Extract, on Hepatic Glucose Production

1,†
,
1,2,†
and
1,2,3,*
1
College of Pharmacy, Gachon Institute of Pharmaceutical Science, Gachon University, Yeonsu-gu, Incheon 21936, Korea
2
Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Yeonsu-gu, Incheon 21999, Korea
3
Gachon Medical Research Institute, Gil Hospital, Namdong-gu, Incheon 21565, Korea
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Keith B. Glaser
Received: 2 February 2017 / Revised: 25 March 2017 / Accepted: 2 April 2017 / Published: 5 April 2017
View Full-Text   |   Download PDF [1511 KB, uploaded 5 April 2017]   |  

Abstract

Phloroglucinol is a phenolic compound that is one of the major compounds in Ecklonia cava (brown alga). It has many pharmacological activities, but its anti-diabetic effect is not yet fully explored. In this study, we investigated the effect of phloroglucinol on the control of blood glucose levels and the regulation of hepatic glucose production. Phloroglucinol significantly improved glucose tolerance in male C57BL/6J mice fed a high fat diet (HFD) and inhibited glucose production in mouse primary hepatocytes. The expression of phosphoenol pyruvate carboxykinase (PEPCK) and glucose-6-phosphatase mRNA and protein (G6Pase), enzymes involved in gluconeogenesis, were inhibited in liver tissue from phloroglucinol-treated mice and in phloroglucinol-treated HepG2 cells. In addition, phloroglucinol treatment increased phosphorylated AMP-activated protein kinase (AMPK)α in HepG2 cells. Treatment with compound C, an AMPKα inhibitor, inhibited the increase of phosphorylated AMPKα and the decrease of PEPCK and G6Pase expression caused by phloroglucinol treatment. We conclude that phloroglucinol may inhibit hepatic gluconeogenesis via modulating the AMPKα signaling pathway, and thus lower blood glucose levels. View Full-Text
Keywords: Phloroglucinol; gluconeogenesis; PEPCK; G6Pase; AMPKα Phloroglucinol; gluconeogenesis; PEPCK; G6Pase; AMPKα
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Yoon, J.-Y.; Choi, H.; Jun, H.-S. The Effect of Phloroglucinol, A Component of Ecklonia cava Extract, on Hepatic Glucose Production. Mar. Drugs 2017, 15, 106.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top